Cargando…
Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical inf...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148954/ https://www.ncbi.nlm.nih.gov/pubmed/35651784 http://dx.doi.org/10.3389/fonc.2022.861392 |
_version_ | 1784717115368931328 |
---|---|
author | Su, Rongjia Jin, Chengwen Bu, Hualei Xiang, Jiangdong Zhou, Lina Jin, Chengjuan |
author_facet | Su, Rongjia Jin, Chengwen Bu, Hualei Xiang, Jiangdong Zhou, Lina Jin, Chengjuan |
author_sort | Su, Rongjia |
collection | PubMed |
description | BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical information of cervical cancer samples were downloaded from TCGA and UCSC Xena website. Immunophenoscore of immune infiltration cells in cervical cancer samples was calculated through the ssGSEA method using GSVA package. WGCNA, Cox regression analysis, LASSO analysis, and GSEA analysis were performed to classify cervical cancer prognosis and explore the biological signaling pathway. RESULTS: There were eight immune infiltration cells associated with prognosis of cervical cancer. Through WGCNA, 153 genes from 402 immune-related genes were significantly correlated with prognosis of cervical cancer. A 15-gene signature demonstrated powerful predictive ability in prognosis of cervical cancer. GSEA analysis showed multiple signaling pathways containing Programmed cell death ligand-1 (PD-L1) expression and PD-1 checkpoint pathway differences between high-risk and low-risk groups. Furthermore, the 15-gene signature was associated with multiple immune cells and immune infiltration in tumor microenvironment. CONCLUSION: The 15-gene signature is an effective potential prognostic classifier in the immunotherapies and surveillance of cervical cancer. |
format | Online Article Text |
id | pubmed-9148954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91489542022-05-31 Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer Su, Rongjia Jin, Chengwen Bu, Hualei Xiang, Jiangdong Zhou, Lina Jin, Chengjuan Front Oncol Oncology BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical information of cervical cancer samples were downloaded from TCGA and UCSC Xena website. Immunophenoscore of immune infiltration cells in cervical cancer samples was calculated through the ssGSEA method using GSVA package. WGCNA, Cox regression analysis, LASSO analysis, and GSEA analysis were performed to classify cervical cancer prognosis and explore the biological signaling pathway. RESULTS: There were eight immune infiltration cells associated with prognosis of cervical cancer. Through WGCNA, 153 genes from 402 immune-related genes were significantly correlated with prognosis of cervical cancer. A 15-gene signature demonstrated powerful predictive ability in prognosis of cervical cancer. GSEA analysis showed multiple signaling pathways containing Programmed cell death ligand-1 (PD-L1) expression and PD-1 checkpoint pathway differences between high-risk and low-risk groups. Furthermore, the 15-gene signature was associated with multiple immune cells and immune infiltration in tumor microenvironment. CONCLUSION: The 15-gene signature is an effective potential prognostic classifier in the immunotherapies and surveillance of cervical cancer. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9148954/ /pubmed/35651784 http://dx.doi.org/10.3389/fonc.2022.861392 Text en Copyright © 2022 Su, Jin, Bu, Xiang, Zhou and Jin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Su, Rongjia Jin, Chengwen Bu, Hualei Xiang, Jiangdong Zhou, Lina Jin, Chengjuan Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title | Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title_full | Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title_fullStr | Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title_full_unstemmed | Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title_short | Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer |
title_sort | development and validation of an immune-related prognostic signature in cervical cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148954/ https://www.ncbi.nlm.nih.gov/pubmed/35651784 http://dx.doi.org/10.3389/fonc.2022.861392 |
work_keys_str_mv | AT surongjia developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer AT jinchengwen developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer AT buhualei developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer AT xiangjiangdong developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer AT zhoulina developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer AT jinchengjuan developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer |